Running Point Capital Advisors’s Gilead Sciences GILD Stock Holding History

Running Point Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$232K	Sell	1,893 -4	-0.2%	-$486	0.06%	117
2025 Q3	$211K	Sell	1,897 -1	-0.1%	-$114	0.06%	121
2025 Q2	$210K	Buy	1,898 +4	+0.2%	+$426	0.06%	119
2025 Q1	$212K	Buy	+1,894	New	+$195K	0.07%	113
2024 Q1	–	Sell	-2,521	Closed	-$204K	–	150
2023 Q4	$204K	Buy	+2,521	New	+$196K	0.1%	98

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Running Point Capital Advisors's GILD Position: Q4 2025 in Review

Running Point Capital Advisors reduced its Gilead Sciences (GILD) stake by 0.21% in Q4 2025, selling an estimated $486 and leaving 1,893 shares worth $232K. The position accounts for 0.06% of the portfolio, ranked #117.

Running Point Capital Advisors first reported a position in GILD in Q4 2023 and has held it in 5 quarters since. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

Running Point Capital Advisors held 1,893 shares of Gilead Sciences worth $232K as of Q4 2025.
Running Point Capital Advisors sold 4 Gilead Sciences shares in Q4 2025, an estimated $486.
Gilead Sciences made up 0.06% of Running Point Capital Advisors's portfolio in Q4 2025, its #117 holding.
Running Point Capital Advisors first reported a position in Gilead Sciences in Q4 2023 and has held it in 5 quarters since.
2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Running Point Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.